Actively Recruiting
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Led by Kestrel Therapeutics, Inc. · Updated on 2026-05-12
145
Participants Needed
7
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutations.
CONDITIONS
Official Title
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Willing and able to give written informed consent
- Histologically confirmed locally advanced unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor
- Documented KRAS mutation before first dose of trial drug
- Disease progression on or intolerance to standard treatments
- ECOG Performance Status of 0 or 1
- Adequate cardiovascular, hematological, liver, and kidney function
- Measurable disease at baseline per RECIST 1.1 criteria
You will not qualify if you...
- Previous or current treatment with RAS or KRAS inhibitors
- Tumors or metastases in the central nervous system
- Inability to swallow oral medications
- Pregnant, breastfeeding, or planning to conceive or father children during the trial period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
2
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
3
Mass General Brigham Cancer Institute at Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
4
Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
5
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
6
NEXT Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
7
NEXT Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
K
Kestrel Therapeutics, Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here